SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Directorate Changes

5 January 2026 - SkinBioTherapeutics, (AIM: SBTX), a life science company focused on skin health, announces the appointment of Alyson Levett as new non-executive director and Chair of the Audit Committee and the promotion of Emily Bertram to Chief Financial Officer and also to the Board. Danielle Bekker has stepped down from the Board but will continue to support as an external advisor effective from 31 December 2025. The appointments came into effect from 1 January 2026.

Alyson Levett, Non-Executive Director and Chair of Audit Committee

Alyson Levett is a highly experienced non-executive Director and Chair of Audit & Risk Committees. She has worked in a broad range of sectors including FMCG, food manufacturing, engineering and technology, with proven expertise with AIM companies and a wealth of shareholder and other stakeholder engagement and relationship experience. She has over 20 years C suite financial experience, culminating in being CFO at the strategy software company, i-nexus where she stayed for a decade taking it onto AIM in a successful IPO in 2018. She left to develop a portfolio Non-Executive career, focussing on the role of Chair of the Audit Committee or Audit & Risk Committee. Her current directorships are listed below, but include GETECH Group plc, Eleco plc and the Financial Services Compensation Scheme. She also acts as a Trustee on the charitable trust,  En-Fold Autism Support, and is a volunteer advisor at The Cranfield Trust. She read Economics at Cambridge University and is a qualified Chartered accountant (ICAEW).

Emily Bertram, Chief Financial Officer and Executive Officer to the Board

Emily Bertram has been promoted from Group Finance Director to Chief Financial Officer and has become an executive Director on the Board of SkinBioTherapeutics, following the AGM. Emily is an experienced certified Chartered Accountant (ACCA) who has led and worked within finance teams in a variety of industries, from business advisory groups to medical technology and pharma companies, to banking. Before SkinBioTherapeutics, Emily was Group Head of Financial Planning and Analysis at Azets, the international business advisory group. Prior to this, she held senior finance positions at THF Holdings, Leica Biosystems, Quantum Pharma, Northumbria University (Faculty of Health & Life Sciences), Alta Link and Northern Rock. She has a 1st class BA (Hons) in Accounting from Northumbria University.

Martin Hunt, Chairman of SkinBioTherapeutics, said:

"On behalf of the Board, I'm delighted to welcome both Alyson and Emily to the Board, and congratulate Emily on her promotion. I'd also like to thank Cathy Prescott for the work she's done as Chair of the Audit Committee and for Danielle for staying on as an advisor. These appointments strengthen the Board, especially the financial elements and provide welcome support to the Executive Management as we enter a busy 2026."

-Ends-

The following information is disclosed pursuant to rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies:

-Ends-   

For more information please contact:

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix^®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix^®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix^® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products. 

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.